Novel therapeutic strategies targeting vascular endothelium in essential hypertension

Dimitris Tousoulis1, Nikolaos Papageorgiou, Emmanouil Androulakis

  • 1Athens University Medical School, Hippokration Hospital, First Cardiology Unit, Athens, Greece. drtousoulis@hotmail.com

Insights

Essential hypertension is strongly linked to endothelial dysfunction. Novel agents show promise in improving vascular health, but further large-scale studies are needed to confirm their efficacy in treating hypertension.

Area of Science:

  • Cardiovascular Medicine
  • Vascular Biology
  • Pharmacology

Background:

  • Hypertension is highly prevalent globally.
  • Endothelial dysfunction is closely associated with hypertension.
  • Understanding this link is vital for effective treatment.

Purpose of the Study:

  • To explore the pathophysiological mechanisms connecting endothelial dysfunction and hypertension.
  • To evaluate therapeutic strategies targeting the vascular endothelium in essential hypertension.

Main Methods:

  • Review of existing literature on essential hypertension and endothelial function.
  • Analysis of classical and novel therapeutic agents.
  • Focus on agents impacting endothelial dysfunction.

Main Results:

  • A bidirectional relationship exists between essential hypertension and endothelial dysfunction.
  • Classical antihypertensives, statins, tetrahydrobiopterin, l-arginine, antioxidants, sildenafil, and NO-related agents show benefits.
  • These agents improve endothelial dysfunction in hypertensive states.

Conclusions:

  • Essential hypertension and endothelial dysfunction have a significant bidirectional association.
  • Novel therapeutic agents demonstrate potential for improving endothelial function in hypertension.
  • More extensive research, including large-scale trials, is necessary to validate these findings.
Abstract

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...